Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Dutton Report

Dutton Report

posted on Nov 27, 2006 07:08AM
November 27, 2006 01:00 PM Atlantic Time (Caribbean)

Dutton Associates Announces Investment Opinion: Patriot Scientific Coverage Initiated with Speculative Buy Rating By Dutton Associates

NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates its coverage of Patriot Scientific Corporation (OTCBB:PTSC) with a Speculative Buy rating and a 12-month price target of $1.06. The 21-page report by Dutton Associates senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals. Patriot Scientific has begun to execute its new strategy to become a dedicated Intellectual Property company by licensing its portfolio of microprocessor patents and has already granted licenses to 11 major microprocessor manufacturers. Patriot Scientific's portfolio of microprocessor patents runs until 2015.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 28 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The current cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 11/27/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Contacts

Dutton Associates, LLC.
John M. Dutton, 916-941-8119

At A Glance
JM Dutton & Associates
Source: via Business Wire
Updated 07/21/2003 by company

Nov 27, 2006 07:33AM

Nov 27, 2006 08:00AM

Nov 27, 2006 09:09AM

Nov 27, 2006 09:34AM

Nov 27, 2006 10:40AM
Share
New Message
Please login to post a reply